Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.
- 1 October 1989
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 86 (19) , 7397-7401
- https://doi.org/10.1073/pnas.86.19.7397
Abstract
To determine which of the 86 amino acids in the Tat protein of human immunodeficiency virus type 1 (HIV-1) are important for transactivation, peptides from Tat were synthesized on their activity was measured in cells containing a chloramphenicol acetyltransferase reporter gene under control of the HIV long terminal repeat promoter. Although the Tat sequence contains arginine- and cysteine-rich stretches that are difficult to synthesize, it was possible to prepare pure peptides in good yield by using fluoren-9-ylmethoxycarbonyl (Fmoc) chemistry. A peptide containing residues 1-58 had 5-10% the activity of full-length Tat. Deleting 4 amino acids from the N terminus of this peptide further reduced deletions and peptides with more extensive N-terminal deletions and peptides missing the basic region at the C terminus had no detectable activity. A peptide previously reported to transactivate, Tat-(37-62), was completely inactive in our assay. Inactive peptides were also tested as possible inhibitors of transactivation. Tat-(21-38), which contains the cysteine-rich region and can form heterodimers with intact Tat in vitro, showed inhibition at high peptide concentrations. However, this effect was not specific for Tat or for the HIV promoter, since the peptide also inhibited expression from the simian virus 40 early promoter.This publication has 35 references indexed in Scilit:
- Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expressionCell, 1989
- HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNACell, 1986
- Trans-activation of human immunodeficiency virus occurs via a bimodal mechanismCell, 1986
- The trans-activator gene of the human T cell lymphotropic virus type III is required for replicationCell, 1986
- Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type IIINature, 1986
- Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificityVirology, 1986
- Location of the Trans -Activating Region on the Genome of Human T-Cell Lymphotropic Virus Type IIIScience, 1985
- Trans -Activator Gene of Human T-Lymphotropic Virus Type III (HTLV-III)Science, 1985
- The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeatCell, 1985
- Trans -Acting Transcriptional Regulation of Human T-Cell Leukemia Virus Type III Long Terminal RepeatScience, 1985